Role of Anterior Segment Optical Coherence Tomography in Infectious Keratitis

March 28, 2023 updated by: Ahemd Abdelghany, Minia University

Role of Anterior Segment Optical Coherence Tomography in Staging and Evaluation of Treatment Response in Infectious Keratitis

To evaluate the role of anterior segment optical coherence tomography in follow up of infectious keratitis and assessment of response to treatment.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

50 patients with proven infectious keratitis clinically will be included in the study.

The following will be performed for all patients in initial visit and follow up:

  • Slit lamp examination and photography.
  • Visual acuity assessment.

  • Anterior segment optical coherence tomography.

    1. The central corneal thickness (CCT) (extracted from pachymetry map),
    2. Minimal corneal thickness (MCT) (extracted from pachymetry map)
    3. Corneal thickness at the site of the lesion (CTL) (extracted from pachymetry map or the sum of STL+ CETL)
    4. Stromal thickness at the center of the lesion (STL) stromal lesion (extracted from stromal map)
    5. Corneal epithelial thickness over the stromal lesion (CETL) at the center of the lesion (extracted from epithelial map)

Study Type

Observational

Enrollment (Actual)

23

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Minya, Egypt
        • Faculty of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Any case with infective keratitis

Description

Inclusion Criteria:

  • Any case with infectious keratitis (any age) either received medical treatment or not, attending to our department will be included in the study.

Exclusion Criteria:

  • Cases with healed infectious keratitis.
  • Cases presented from the start with severe corneal affection and melting.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
infective keratitis
50 cases with infectious keratitis (any age) either received medical treatment or not, attending to our department will be included in the study.
Other: Optical coherence tomography
Anterior segment optical coherence tomography examination of corneas with infective keratitis

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
criteria of lesion on optical coherence tomography
Time Frame: 1 month
Localiztion, depth of infiltration area in microns
1 month
width of lesion on optical coherence tomography
Time Frame: 1 month
width of infiltration in microns
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Minia University

Investigators

  • Principal Investigator: Ahmed Abdelghany, ASS PROF, Minia University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2021

Primary Completion (Actual)

December 31, 2021

Study Completion (Actual)

December 31, 2021

Study Registration Dates

First Submitted

June 25, 2021

First Submitted That Met QC Criteria

July 16, 2021

First Posted (Actual)

July 21, 2021

Study Record Updates

Last Update Posted (Actual)

March 29, 2023

Last Update Submitted That Met QC Criteria

March 28, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 43:6/2021

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe